Physician profile
Ankit Ashwin Patel
NPI 1083979322
$19,771.78
in general payments reported to CMS, 2019-2025
81 companies · $3,026 in 2025
The $3,026 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,142 · 2020: $1,997 · 2021: $2,927 · 2022: $3,368 · 2023: $3,294 · 2024: $3,018 · 2025: $3,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,171 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,170.84 |
| Education | $166.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,101.16 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $1,228.98 | 2021-2025 | |
| Ucb, INC. | $1,199.69 | 2019-2025 | Rystiggo, Fintepla, Briviact |
| Novartis Pharmaceuticals Corporation | $1,114.39 | 2019-2025 | |
| Sk Life Science, INC. | $1,091.53 | 2020-2025 | |
| Genentech USA, INC. | $935.50 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Emd Serono, INC. | $758.75 | 2020-2025 | Mavenclad |
| Acadia Pharmaceuticals INC | $699.72 | 2019-2025 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $677.75 | 2021-2025 | Hyqvia, Gammagard |
| Abbott Laboratories | $668.74 | 2019-2025 | Infinity |
| Pfizer INC. | $633.87 | 2019-2025 | |
| Genzyme Corporation | $628.11 | 2019-2022 | |
| Lilly USA, LLC | $501.41 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Alexion Pharmaceuticals, INC. | $442.07 | 2019-2025 | Ultomiris |
| Sunovion Pharmaceuticals INC. | $408.28 | 2019-2022 |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $406.69 | 2020-2025 | Valtoco |
| Biogen, INC. | $320.58 | 2019-2025 | Vumerity, Plegridy, Avonex |
| Grifols USA, LLC | $296.38 | 2019-2025 | Gamunex-C |
| Celgene Corporation | $279.57 | 2022-2025 | Zeposia |
| Lundbeck LLC | $273.98 | 2020-2025 | Rexulti, Vyepti |
| Eisai INC. | $268.04 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $266.51 | 2023-2024 | Aptiom |
| Boston Scientific Corporation | $240.13 | 2019-2025 | Vercise, General - Dbs |
| Neurocrine Biosciences, INC. | $234.82 | 2020-2025 | Ingrezza, Ongentys |
| Amgen INC. | $230.62 | 2020-2023 | Aimovig |
| Jazz Pharmaceuticals INC. | $226.63 | 2019-2024 | |
| Argenx US, INC. | $224.91 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Janssen Pharmaceuticals, INC | $189.81 | 2021-2022 | |
| Ge Healthcare | $173.14 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $163.42 | 2023-2025 | Rexulti, Nuedexta |
| Amneal Pharmaceuticals LLC | $160.65 | 2019-2025 | Crexont, Rytary |
| Medtronic, INC. | $154.76 | 2021-2025 | Percept Pc Brainsense, Activa Pc |
| Mallinckrodt Hospital Products INC. | $154.22 | 2020-2021 | |
| Harmony Biosciences LLC | $153.00 | 2020-2022 | |
| Upsher-Smith Laboratories LLC | $148.71 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $138.84 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $109.64 | 2019 | |
| Acorda Therapeutics, INC | $105.18 | 2019-2023 | Inbrija, Ampyra |
| Kyowa Kirin, INC. | $101.64 | 2020-2024 | Nourianz |
| Csl Behring | $99.79 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $95.05 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $92.89 | 2021-2025 | Wainua |
| Adamas Pharmaceuticals, INC. | $87.33 | 2019-2021 | |
| Octapharma USA, INC. | $82.87 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $81.66 | 2022 | |
| F. Hoffmann-La Roche Ag | $80.00 | 2025 | |
| Allergan, INC. | $71.76 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $68.83 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $63.33 | 2022-2024 | Quviviq |
| Avion Pharmaceuticals | $57.30 | 2022-2023 | Dhivy |
| Aquestive Therapeutics, INC. | $56.89 | 2019-2022 | |
| Axsome Therapeutics, INC. | $53.97 | 2022-2025 | Sunosi |
| Medtronic USA, INC. | $52.54 | 2019-2020 | |
| Assertio Therapeutics, INC. | $45.34 | 2019-2020 | |
| Aprecia Pharmaceuticals, LLC | $39.93 | 2023 | Spritam |
| Livanova USA, INC. | $38.99 | 2020-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Hospira, INC. | $36.10 | 2024-2025 | |
| Aucta Pharmaceuticals, INC. | $34.88 | 2024 | Motpoly Xr |
| Avanir Pharmaceuticals, INC. | $31.66 | 2019 | |
| Endo Pharmaceuticals INC. | $31.14 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $30.71 | 2020 | |
| Bard Peripheral Vascular, INC. | $30.58 | 2024 | Pristine |
| Currax Pharmaceuticals LLC | $26.14 | 2021-2022 | |
| Tg Therapeutics, INC. | $24.93 | 2023 | |
| Collegium Pharmaceutical, INC. | $23.46 | 2022 | |
| Nevro Corp. | $23.25 | 2022 | |
| Janssen Biotech, INC. | $23.19 | 2025 | |
| Grt US Holding, INC. | $23.11 | 2021 | |
| Horizon Therapeutics Plc | $21.05 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $19.86 | 2022 | |
| Amarin Pharma, INC. | $18.64 | 2020 | |
| Azurity Pharmaceuticals, INC. | $16.96 | 2024 | Horizant |
| Insightec,INC | $16.32 | 2023 | Exablate |
| Ani Pharmaceuticals, INC. | $16.00 | 2023 | Purified Cortrophin Gel |
| Vertical Pharmaceuticals, LLC | $14.84 | 2019 | |
| Corium, LLC | $14.48 | 2023 | Adlarity |
| Banner Life Sciences, LLC | $14.19 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.